TIMP3 and breast carcinoma: In colorectal cancer (Supplementary Figures S4A, D), head and neck squamous cell carcinoma (Supplementary Figures S4B, E), and breast cancer (Supplementary Figures S4C, F), the predicted survival of patients with high expression of TIMP3 was lower than that predicted by patients with low expression of TIMP3, while at the same time the expression of TIMP3 was negatively correlated with the number of cytotoxic T-lymphocytes, a result which further illustrates that high expressing TIMP3 patients were predicted to have lower survival.